Clinuvel Pharmaceuticals (HAM:UR9) Total Liabilities: €11.74 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:UR9 Clinuvel Pharmaceuticals Ltd HAM:UR9
80 GF Score
Price €6.00
GF Value €10.76
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Total Liabilities?

Clinuvel Pharmaceuticals HAM:UR9 -1.12% 80 Total Liabilities is €11.74 Mil as of Dec. 2025. GuruFocus rates HAM:UR9 with a GF Score™ of 80/100 and a GF Value™ of €10.76. The stock has 2 warning signs investors should review.

Clinuvel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was €11.74 Mil.

Clinuvel Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2024 (€11.43 Mil) to Jun. 2025 (€17.47 Mil) but then declined from Jun. 2025 (€17.47 Mil) to Dec. 2025 (€11.74 Mil).

Clinuvel Pharmaceuticals's annual Total Liabilities declined from Jun. 2023 (€18.02 Mil) to Jun. 2024 (€17.34 Mil) but then increased from Jun. 2024 (€17.34 Mil) to Jun. 2025 (€17.47 Mil).

Clinuvel Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals Total Liabilities Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.24 12.23 18.02 17.34 17.47

Clinuvel Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.27 17.34 11.43 17.47 11.74
HAM:UR9
80GF Score
Clinuvel Pharmaceuticals Ltd HAM:UR9
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinuvel Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Clinuvel Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.359+(0.055+0.049
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1.93+0.072+0)
=17.47

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=153.39-135.925
=17.47

Clinuvel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.129+(0.01+0.107
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1.489+0+0)
=11.74

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=153.037-141.302
=11.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €11.74 Mil mean?
Clinuvel Pharmaceuticals (HAM:UR9) has a Total Liabilities of €11.74 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Clinuvel Pharmaceuticals and its competitors.
Is Clinuvel Pharmaceuticals' Total Liabilities too high?
Clinuvel Pharmaceuticals' current Total Liabilities is €11.74 Mil. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Total Liabilities compare to VRTX and REGN?
Clinuvel Pharmaceuticals' Total Liabilities of €11.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Total Liabilities is €11.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Clinuvel Pharmaceuticals (HAM:UR9) has a current Total Liabilities of €11.74 Mil. The stock's GF Value™ is €10.76, compared to a current price of €6.00 — trading 44.2% below its estimated fair value. The current Total Liabilities is €11.74 Mil. Clinuvel Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (HAM:UR9), the current Total Liabilities is €11.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (HAM:UR9) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of €6.00 is trading 44.2% below its estimated GF Value™ of €10.76.

Key valuation signals for HAM:UR9:

  • Total Liabilities: €11.74 Mil
  • GF Value™: €10.76 vs. price of €6.00 (44.2% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the HAM:UR9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
80GF Score

Get the complete analysis for HAM:UR9

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€10.76
GF Value